Adenovirus-vectored African Swine Fever Virus Antigens Cocktail Is Not Protective against Virulent Arm07 Isolate in Eurasian Wild Boar

• Published in: Pathogens (Basel) Vol. 9; no. 3; p. 171
• Main Authors: Cadenas-Fernández, Estefanía, Sánchez-Vizcaíno, Jose M, Kosowska, Aleksandra, Rivera, Belén, Mayoral-Alegre, Francisco, Rodríguez-Bertos, Antonio, Yao, Jianxiu, Bray, Jocelyn, Lokhandwala, Shehnaz, Mwangi, Waithaka, Barasona, Jose A
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 28.02.2020; MDPI AG
• Subjects: adenovirus; african swine fever; armenia07/arm07; eurasian wild boar; immune response; protective efficacy; subunit vaccine; Armenia07/Arm07; subunit vaccine; African swine fever; protective efficacy; immune response; Eurasian wild boar; adenovirus
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens9030171

African swine fever (ASF) is a viral disease of domestic and wild suids for which there is currently no vaccine or treatment available. The recent spread of ASF virus (ASFV) through Europe and Asia is causing enormous economic and animal losses. Unfortunately, the measures taken so far are insufficient and an effective vaccine against ASFV needs to be urgently developed. We hypothesized that immunization with a cocktail of thirty-five rationally selected antigens would improve the protective efficacy of subunit vaccine prototypes given that the combination of fewer immunogenic antigens (between 2 and 22) has failed to elicit protective efficacy. To this end, immunogenicity and efficacy of thirty-five adenovirus-vectored ASFV antigens were evaluated in wild boar. The treated animals were divided into different groups to test the use of BioMize adjuvant and different inoculation strategies. Forty-eight days after priming, the nine treated and two control wild boar were challenged with the virulent ASFV Arm07 isolate. All animals showed clinical signs and pathological findings consistent with ASF. This lack of protection is in line with other studies with subunit vaccine prototypes, demonstrating that there is still much room for improvement to obtain an effective subunit ASFV vaccine.